WO2009110816A1 - Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение - Google Patents
Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение Download PDFInfo
- Publication number
- WO2009110816A1 WO2009110816A1 PCT/RU2008/000122 RU2008000122W WO2009110816A1 WO 2009110816 A1 WO2009110816 A1 WO 2009110816A1 RU 2008000122 W RU2008000122 W RU 2008000122W WO 2009110816 A1 WO2009110816 A1 WO 2009110816A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- liver
- hepatoprotector
- prebiotic
- acid
- Prior art date
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 title description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 94
- 210000004185 liver Anatomy 0.000 claims abstract description 63
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 44
- 208000019423 liver disease Diseases 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 37
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims abstract description 15
- 231100000331 toxic Toxicity 0.000 claims abstract description 15
- 230000002588 toxic effect Effects 0.000 claims abstract description 15
- 206010067125 Liver injury Diseases 0.000 claims abstract description 11
- 210000000232 gallbladder Anatomy 0.000 claims abstract description 11
- 231100000234 hepatic damage Toxicity 0.000 claims abstract description 9
- 230000008818 liver damage Effects 0.000 claims abstract description 9
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 8
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims abstract description 5
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims abstract description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 38
- 239000003613 bile acid Substances 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 29
- 150000003904 phospholipids Chemical class 0.000 claims description 23
- 229960000511 lactulose Drugs 0.000 claims description 19
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 19
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 16
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 15
- 201000001883 cholelithiasis Diseases 0.000 claims description 14
- 229960003964 deoxycholic acid Drugs 0.000 claims description 12
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 12
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 11
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 9
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims description 9
- 230000001771 impaired effect Effects 0.000 claims description 9
- 230000004060 metabolic process Effects 0.000 claims description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims description 8
- 206010051914 Cholesterosis Diseases 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 7
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 7
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 7
- -1 or globules Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 5
- 241000320380 Silybum Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 235000010841 Silybum marianum Nutrition 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920001592 potato starch Polymers 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004380 Cholic acid Substances 0.000 claims description 3
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 235000019416 cholic acid Nutrition 0.000 claims description 3
- 229960002471 cholic acid Drugs 0.000 claims description 3
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229960004245 silymarin Drugs 0.000 claims description 3
- 235000017700 silymarin Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 229960001661 ursodiol Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000014899 silybin Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000000419 plant extract Substances 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- XQKRPEDJRVOOAA-UHFFFAOYSA-J [Mg+2].[Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O Chemical compound [Mg+2].[Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XQKRPEDJRVOOAA-UHFFFAOYSA-J 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- 229940099347 glycocholic acid Drugs 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229940043175 silybin Drugs 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 201000010099 disease Diseases 0.000 abstract description 15
- 230000000968 intestinal effect Effects 0.000 abstract description 12
- 206010004659 Biliary cirrhosis Diseases 0.000 abstract description 4
- 230000009044 synergistic interaction Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000005213 imbibition Methods 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 description 34
- 238000000034 method Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 22
- 210000000936 intestine Anatomy 0.000 description 22
- 230000007423 decrease Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 241000186660 Lactobacillus Species 0.000 description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 17
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 208000027244 Dysbiosis Diseases 0.000 description 14
- 230000007140 dysbiosis Effects 0.000 description 14
- 210000003494 hepatocyte Anatomy 0.000 description 14
- 210000000813 small intestine Anatomy 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 13
- 238000010606 normalization Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 244000005709 gut microbiome Species 0.000 description 12
- 244000005706 microflora Species 0.000 description 12
- 238000002604 ultrasonography Methods 0.000 description 12
- 241000186000 Bifidobacterium Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 150000002482 oligosaccharides Chemical class 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000006041 probiotic Substances 0.000 description 10
- 235000018291 probiotics Nutrition 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 206010019799 Hepatitis viral Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 238000001784 detoxification Methods 0.000 description 8
- 230000037356 lipid metabolism Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 229960003080 taurine Drugs 0.000 description 8
- 201000001862 viral hepatitis Diseases 0.000 description 8
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 7
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000002443 hepatoprotective effect Effects 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Natural products CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000003445 biliary tract Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010008617 Cholecystitis chronic Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000005844 Thymol Substances 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 201000001352 cholecystitis Diseases 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960000790 thymol Drugs 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000008789 Direct Bilirubin Methods 0.000 description 4
- 206010019842 Hepatomegaly Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 208000036649 Dysbacteriosis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical group O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229960001570 ademetionine Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000002202 anti-cholestatic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000009429 distress Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000021149 fatty food Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 3
- 230000007872 intrahepatic cholestasis Effects 0.000 description 3
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 208000007232 portal hypertension Diseases 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 108010014831 7-alpha-hydroxysteroid dehydrogenase Proteins 0.000 description 2
- 101100038180 Caenorhabditis briggsae rpb-1 gene Proteins 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-fructofuranose group Chemical group OCC1(O)[C@@H](O)[C@H](O)[C@H](O1)CO RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241001662043 Icterus Species 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000001989 choleretic effect Effects 0.000 description 2
- 230000001587 cholestatic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RVEWUBJVAHOGKA-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;2-aminopentanedioic acid Chemical compound OC(=O)C(N)CCC(O)=O.OC(=O)C(N)CCCN=C(N)N RVEWUBJVAHOGKA-UHFFFAOYSA-N 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102100036093 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Human genes 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 206010048714 Gastroduodenitis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102100039215 Guanine nucleotide-binding protein G(t) subunit alpha-3 Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101000876377 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Proteins 0.000 description 1
- 101000888145 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-3 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058117 Ocular icterus Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Natural products NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031353 Systolic Murmurs Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940078967 bile acid preparations for bile therapy Drugs 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000002181 esophagogastroduodenoscopy Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001570 microsomal oxidation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009024 positive feedback mechanism Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- IYPNVUSIMGAJFC-JUWYWQLMSA-M sodium;2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)CC1 IYPNVUSIMGAJFC-JUWYWQLMSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- composition based on hepatoprotector and prebiotic, preparation and use
- the invention relates to medicine, in particular to hepatology and pharmacology and can be used to obtain and use a pharmaceutical composition based on hepatoprotector and prebiotic for the treatment and prevention of liver diseases selected from the group: gallstone disease, fatty hepatosis and non-alcoholic steatohepatitis, primary biliary cirrhosis liver, gallbladder cholesterosis, drug and toxic liver damage.
- liver diseases selected from the group: gallstone disease, fatty hepatosis and non-alcoholic steatohepatitis, primary biliary cirrhosis liver, gallbladder cholesterosis, drug and toxic liver damage.
- liver diseases the main organ of detoxification of exogenous poisons.
- reasons for the increase in liver morbidity are environmental dysfunction in most parts of the world.
- the source of infection in viral hepatitis is a sick person, the transmission route is either fecal-oral or parenteral, depending on the type of virus: A, B, C, D, G, E.
- the susceptibility of the population to this infection is high.
- the virus eventually enters the liver, where it has a direct toxic effect on liver cells, which is combined with immune-mediated damage to their membranes.
- cholestatic syndrome With all forms of viral hepatitis, one of the frequent serious complications is a violation of the normal processes of formation and secretion of bile, the so-called cholestatic syndrome, accompanied by jaundice. Most often it manifests itself in viral hepatitis A (HAV) - "enteric" viral hepatitis and in viral hepatitis E, in which the frequency of icteric forms is
- liver morbidity In addition to viral hepatitis, a significant proportion of liver morbidity is associated with exposure to food toxicants (alcohol, other toxic substances, various medicines).
- liver damage One of the earliest pathological complications of toxic liver damage is steatohepatitis - a consequence of a disturbance in the normal balance between the intake of fats in the body and their metabolism.
- liver diseases one of the important etiological and pathogenetic factors is the violation of normal metabolic processes of bile acids (FA) - one of the most important factors in normal digestion.
- FA bile acids
- FAs are formed in the liver from cholesterol (Hofmarm AF. BiIe acid slitopiop, bilé flów apd biliár liirid sécretiop ip humap. Neratologi. 1990; 12;
- the main FAs found in human bile are cholic acid (XK) (Za, 7a, 12a-troxy-5b-cholic acid), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA) (Za,
- XK and CDCA the so-called primary FAs
- primary FAs are formed in the liver during the oxidation of cholesterol
- DCA and JIXK are formed from primary FAs in the intestine under the influence of enzymes of microorganisms of the intestinal microflora.
- the quantitative ratio of XK, HDCA and DHA in bile is normally 1: 1: 0.6.
- FAs are present mainly as paired compounds - conjugates.
- FAs are absorbed into the blood, return to the liver with blood and are again secreted as part of bile - this is the so-called portal-biliary circulation of FAs, therefore 85 - 90% of the total amount of FAs contained in bile constitute FA absorbed in the intestine.
- FA conjugates easily absorbed in the intestine, as they are water-soluble, while in the intestine 10 - 15% of the total number of FAs is cleaved by the enzymes of the microorganisms of the intestinal microflora, and their degradation products are excreted in the feces.
- FA emulsifying fats
- FAs have a strong choleretic effect, stimulate intestinal motility, and also have bacteriostatic and anti-inflammatory effects.
- a possible component of the method of treatment and prevention of many pathological conditions of the liver is the use of bile acid preparations, primarily UDCA.
- UDCA is a tertiary bile acid, first discovered in the bile of a Chinese bear in 1902.
- UDCA has been used in medicine for several centuries: even in ancient China, dried bear bile was prescribed in the treatment of diseases of the stomach, intestines and liver.
- UDCA is formed by bacterial enzymes from
- UDCA becomes the main component of bile, while the content of CDCA and other FAs decreases.
- a lower accumulation of UDCA in bile is observed in patients with liver diseases, which may be associated with a decrease in absorption due to a decrease in the formation of endogenous micelles from bile acids in duodenal bile or with a decrease in secretion of bile acids themselves.
- UDCA and JIXK are found in human bile as mentioned above, only in very small quantities (0.1% - 5%).
- UDCA and its conjugates which are not absorbed in the small intestine, are metabolized in the distal small intestine and colon by indigenous bacteria.
- JIXK lithocholic acid
- JIXK which is contained in human bile in very small quantities, is formed in the small intestine under the influence of microflora in the process of utilization of many fats; from the small intestine, JIXK enters the colon and rectum, where it is partially absorbed and enters the liver. In the liver, JIXK binds to sulfate anions, then to glycine and taurine, and thus is secreted into bile. Its derivatives are little absorbed in the intestine and excreted through the stool.
- Such a process is an effective mechanism for eliminating toxic JIXK from the body.
- HDCA causes a decrease in the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase, an enzyme involved in the synthesis of cholesterol, and also helps to reduce cholesterol absorption in the intestine, which leads to a change in the ratio of bile acids and cholesterol to the side in which the total bile acid pool prevails
- the above mechanisms determine the use of HDCA in the dissolution of gallstones, consisting mainly of cholesterol.
- DCA Deoxycholic acid
- XK and HDCA the main bile acids synthesized in the liver from cholesterol.
- DCA Secondary DCA is formed in the distal parts of the small intestine and in the colon under the influence of intestinal microflora enzymes, namely bacterial 7-alpha-dehydroxylase, from cholic acid. DCA is partially absorbed from the intestine and is involved in the recirculation of bile acids after conjugating it in the liver with taurine or glycine.
- DHA promotes lithogenicity of bile and the formation of calculi by slowing the transit time through the intestine, which, in turn, increases the absorption of cholesterol and, through the positive feedback mechanism, promotes the formation of DHA itself.
- DCA can enhance the secretion of cholesterol into bile by acting on the canalicular membrane of the hepatocyte, where cholesterol is in the sphingomyelin domains, and also enhance crystallization of cholesterol in bile, destabilizing vesicles with cholesterol.
- FAs are present mainly in the form of paired compounds - conjugates.
- GCC glycocholic
- HCDC glycohenodeoxycholic
- taurine (2-aminoethane-sulphonic acid C 2 H 7 O 3 N 5 )
- TXK taurocholic
- T DCA taurodeoxycholic acid
- Conjugation of FA includes the steps of forming KoA - FA esters and combining the FA molecule with glycine or taurine via an amide bond with the participation of the lysosomal acyltransferase enzyme.
- the ratio of glycine and taurine FA conjugates in bile, averaging 3: 1, may vary depending on the composition of the food and the hormonal status of the body.
- metabolic disorders of bile acids is one of the important pathogenetic factors in the development of a number of liver diseases.
- a known method of treatment of the above liver diseases which consists in the use in the form of mono - or complex therapy of drugs UDCA (RU 2002123352 A from 03/27/2004).
- liver diseases There is also a method of treating liver diseases by using HDCA in complex therapy (China Drug Register. Drug Encyclopedia. Editor-in-Chief G.L. Byshkovsky. M .: “PLC-2006", 2005, p. 895 - 896).
- Phospholipids or phosphoglycerides
- phospholipids are important constituents of lipoproteins, "pulmonary surfactants” and bile. They take part in the work of the nervous system, in membrane enzymatic reactions, play an important role in metabolism and oxidative processes. Being part of lipoproteins, phospholipids affect the concentration of cholesterol in the blood.
- Phospholipids located in platelets take part in the process of blood coagulation, which ultimately shows their effect on the protective function of blood and hemodynamics in the body of mammals and humans.
- the chemical structure of phospholipids, their biphilicity, the presence of charged groups determines the uniqueness of their physiological properties.
- phospholipids The main function of phospholipids is the formation of a double lipid layer in cell membranes.
- the structure and function of cell membranes is of extreme importance to human health. A feeling of general malaise, dysfunction and various diseases can in many cases be explained by damage to the membranes or their instability.
- By introducing phospholipids it is possible to influence the membrane functions associated with membrane proteins and correct them, at least to some extent, and sometimes completely correct the impaired function.
- Essential phospholipids mainly penetrate the liver cells, penetrate the hepatocyte membranes, normalize liver functions, metabolize lipids and proteins, promote the activation and protection of phospholipid-dependent enzyme systems, and improve detoxification function of the liver, restore its cellular structure, improve regeneration and inhibit the formation of connective tissue in it.
- the drug reduces the level of energy consumption in the liver, converts neutral fats and cholesterol into easily metabolizable forms, stabilizes the physicochemical properties of bile.
- Essential phospholipids normalize the digestion in the intestines of not only fats, but also solid foods indirectly by restoring the structure of liver cells, which leads to the normalization of bile formation and biliary excretion (Gurevich K.G. Essential phospholipids in the treatment of liver diseases. Qualitative clinical practice. 2002, JMb 4, pp. 108-111).
- Another representative of the group of substances with hepatoprotective properties is the extract from the plant of milk thistle as the main active ingredient in silymarin. Its action is hepatoprotective, regenerating, detoxifying.
- Clinical pharmacology improves the general condition of patients with liver diseases, reduces subjective complaints: weakness, a feeling of heaviness in the right hypochondrium, loss of appetite, vomiting, skin itching, normalizes laboratory parameters: transaminase activity, gamma-glutamyl transferase, alkaline phosphatase, bilirubin level. With prolonged use increases life expectancy patients with cirrhosis of the liver.
- hepatoprotective preparations a number of amino acids or their derivatives are also referred to as hepatoprotective preparations.
- the S-adenosyl-L-methionine (ademethionine) molecule donates a methyl group in the methylation reactions of phospholipids of cell membranes of proteins, hormones, neurotransmitters, etc. (transmethylation). It is a precursor to physiological thiol compounds - cysteine, taurine, glutathione (provides the redox mechanism of cellular detoxification), KoA, and others in trans sulfation reactions.
- the anticholestatic effect is due to increased mobility and polarization of hepatocyte membranes, due to the stimulation of the synthesis of phosphatidylcholine in them. This improves the function of bile acid transport systems (BFAs) associated with hepatocyte membranes and promotes the passage of FAs into the biliary system. Stimulates detoxification of FAs - increases the content of conjugated and sulfated FAs in hepatocytes. Conjugation with taurine increases the solubility of FAs and their removal from hepatocyte.
- BFAs bile acid transport systems
- Sulfation provides the possibility of elimination by the kidneys, facilitates the passage through the membrane of hepatocyte and excretion with bile.
- sulfated FAs protect liver cell membranes from the toxic effects of non-sulfated FAs (present in high concentrations in hepatocytes with intrahepatic cholestasis).
- intrahepatic cholestasis liver damage: toxic, including alcoholic, viral, medicinal (antibiotics, antitumor, antituberculosis, antiviral drugs, tricyclic antidepressants, oral contraceptives); cirrhotic and precirrotic conditions; encephalopathy, including associated with liver failure (alcohol, etc.); depressive and withdrawal syndrome.
- ademetionine In addition to directly affecting liver tissue, ademetionine has a number of additional pharmacological effects, such as antidepressant effect (develops in the first week and stabilizes during the second week of treatment). Also, this drug is empirically used for osteoarthritis, which is accompanied by a decrease in pain and stimulation of proteoglycan synthesis and partial regeneration of cartilage tissue.
- liver diseases usually does not provide a complete cure, and when drugs are withdrawn, relapses or exacerbations of liver diseases often occur, including due to a persistent violation of the intestinal biocenosis, which is persistent in many diseases of the gastrointestinal tract and liver.
- the microflora of the gastrointestinal tract (GIT) and the liver inextricably interact in the processes of detoxification of the body.
- the microbiota in the composition of the biofilm first comes into contact and subsequent metabolic reactions with all substances entering the body with food, water or atmospheric air.
- Microbiota transforms chemicals into non-toxic end products or into intermediates that are easily destroyed in the liver and then removed from the body.
- enterohepatic circulation of various organic and inorganic compounds can, without exaggeration, be considered cardinal homeostatic mechanisms.
- a decrease in the detoxification function of the gastrointestinal microflora in case of dysbiosis due to various pathogens (drugs, food, stress, etc.) increases the load on the enzymatic systems of the liver and, under certain conditions, contributes to the occurrence of metabolic and structural changes in it.
- Prebiotics include, in particular, many oligosaccharides that are not utilized by the human body due to the absence in the intestines of their own enzymes that break down such sugars.
- Indigestible oligosaccharides include, in particular: fructooligosaccharides (FOS), maltooligosaccharides, galactooligosaccharides, inulin, lactulose, and some other oligosaccharides that can be used as prebiotics (Sheveleva CA. Probiotics, prebiotics, and probiotic products. 1999, N ° 2, pp. 33–39; Shoaf Ket al. Rebiotics galastooligosassharides reduce adhepse THERf ⁇ perorath Middlegepis ⁇ demander ⁇ réeller ⁇ vich ⁇ li solo Georgiaulture Northell.
- FOS in terms of chemical structure are oligofructosaccharides in which ⁇ -, D-fructofuranose residues are linked by ⁇ -2, 1-glycosidic bonds and have an ⁇ -glucose residue at one end of the chain connected to the fructose bond ⁇ -1, 2.
- FOS 1-cectosis
- GF 3 nystosis
- GF 4 lF-fructofuranosylnistosis
- FOS have a pronounced prebiotic effect - they are not absorbed in the upper gastrointestinal tract, inhibit the growth of putrefactive microflora, contribute to the normalization of blood pressure and blood lipids, improve the adsorption of calcium and magnesium, increase immunity, have a beneficial effect in constipation and purulent processes; prevent colon cancer.
- FOS like all prebiotics, are not hydrolyzed by enzymes
- the gastrointestinal tract is not absorbed in the small intestine, and, unchanged in the colon, is a selective substrate for the growth of normal microflora.
- Lactulose is a disaccharide consisting of galactose and fructose (4-0-D-galactopyranosyl-D-fructose). Under natural conditions, a small amount of lactulose can form when milk is heated to temperatures above 100 ° C. Lactulose is highly soluble in water and about 1.5 to 2 times sweeter than lactose.
- latulose The prebiotic effect of latulose is manifested due to an increase in the volume of the contents of the colon, a decrease in pH, as well as a decrease in the ammonia content in the colon and an increase in the content of short-chain fatty acids, in particular propionic acid (ZDUNCZYK Z et al. Phospholophilicophosphate and inulin phosphate Rats. Arsh Apim Nutr.- 2004.- Vol. 58 (l). ⁇ P.89-98).
- lactulose Being a prebiotic, lactulose, at the same time, to the present time in therapy is used, mainly or even exclusively, as a mild and effective laxative.
- the laxative effect of lactulose is directly related to the prebiotic effect and is due to an increase in the volume of the contents of the colon (by about 30%) due to an increase in the number of bacterial populations.
- JP indigestible oligosaccharide
- lactulose was used in high doses (about 30 ml of concentrated syrup per person), which are known not only as prebiotic, but as laxatives. At such high doses, lactulose is usually used in hepatology mainly to alleviate the symptoms of hepatic encephalopathy, that is, in palliative symptomatic relief of the condition in patients with almost incurable conditions (late stage cirrhosis). In these situations, the normalization of intestinal microflora is not able to give any long-term effect.
- liver diseases with cholestatic syndrome by using a combination of hepatoprotector of plant origin (extract obtained from Silibum mariapum) with the probiotic strain Lactobasillus bulgaripii and some other substances (BG 108250U from 04/30/2005).
- the positive therapeutic effect is relatively short-lived.
- liver diseases containing alkaline sphingomyelinase as the main active principle, and various substances, including those from the class of probiotics (Lactobacillus acidorhilus, Lactobacillus brisvis, Lactobacillus bachperi, Lactobacillus, satepaform), prebiotics and
- lysosomal enzyme which is used to prevent and / or treat various diseases selected from the group: impaired activity of the small intestine, malignant tumors, disorders of the immune system, inflammation and desquamation of the mucous membrane of the small intestine, conditions associated with impaired cholesterol synthesis , impaired absorption of the small intestine, allergic diseases of the small intestine.
- probiotics Lactobacillus acidorhilus, Lactobacillus brévis, Lactobacillus caséi, etc.
- a bile acid derivative - ursodeoxycholic acid and prebiotic - lactulose.
- this pharmaceutical composition for the treatment of these diseases is not without its main drawback - the short duration of action due to an exogenous probiotic strain. Moreover, those present in the composition prebiotic components are largely utilized by the aforementioned introduced exogenous strain.
- the closest analogue of the claimed invention is a liver function improving agent or component that functions as a methyl group donor and includes a digestible oligosaccharide containing galactose, used as a functional food product (JP 2003-155242 from 05.27.2003).
- the methyl group donor is selected from the group of amino acids, including S-adenosylmethionine
- the galactose-containing oligosaccharide is selected from the group including, lactulose or galactooligosaccharide.
- liver disease different from the closest analogue, for the treatment of which the present pharmaceutical composition has been developed;
- a pharmaceutical composition was developed, including hepatoprotector and prebiotic, selected strictly from a limited number of representatives of these groups of drugs; the feasibility of introducing a hepatoprotector and a prebiotic at the same time in one pharmaceutical composition is shown in view of their synergistic effect on each other;
- the aim of the present invention is to achieve significant, positive effects in the form of accelerating the normalization of health and reducing the severity of symptoms of the disease in the complex treatment of individual liver diseases. Achieving this goal is achieved by using a combined (complex) drug in the treatment of liver diseases containing a mixture of hepatoprotector and prebiotic substance, in particular, oligosaccharides that are not digested in the intestine.
- the technical result to which the present invention is directed is to restore liver function in the shortest possible time and prevent relapse of the disease due to the restoration of cholesterol metabolism and intestinal biocenosis due to the synergistic interaction of hepatoprector and prebiotic, which also leads to the prevention of side effects of the hepatoprotector.
- bile acids / salts of bile acids selected from the group: GHK, GHDKh, TXK, TDKh, UDCA, KDKhK and essential phospholipids.
- the synergistic effect of the hepatoprotector, such as UDCA, and the prebiotic is due to the fact that UDCA normalizes the digestion of not only fats in the intestines, but also solid foods by increasing the synthesis of bile acids and UDCA itself in the liver, which contributes to the normalization of intestinal microflora, and the prebiotic itself , contributes to the normalization of microflora due to stimulation of the growth of resident strains, which entails the manifestation of immunostimulating effects and other effects of normoflora, and as a result, improvement of digestion processes, detoxification shenie exogenous poisons of their own microflora, which also reduces the metabolic load on the liver, helps to normalize the metabolism of fatty acids and cholesterol, which, in turn, has a stabilizing effect on all cells of the body, including hepatocytes.
- the combination of bile acids or salts of bile acids in one pharmaceutical composition with non-digestible oligosaccharides in the small intestine selected from the group: lactulose or FOS, maltooligosaccharides, galactooligosaccharides, inulin allows you to restore the functioning of hepatocytes and the liver as a whole due to the normalization of intestinal biocenosis, which , in turn, provides stabilization of the achieved therapeutic result for a long time.
- the patient’s blood contains an increased content of toxic products coming from the colon to the blood, especially ammonia, a nitro compound that is formed during bacterial decomposition of protein in the colon by proteolytic microflora, which increases the toxic load on the liver.
- the restoration of microflora in the intestine indirectly contributes to an increase in the reduction of the toxic load on the liver and an increase in UDCA in the liver, which, in turn, helps to restore the composition of bile, in particular, to increase bile acids by reducing the synthesis of cholesterol by the liver, and this, in turn, prevents relapse of the disease, in particular gallstone disease with predominantly cholesterol stones.
- the claimed pharmaceutical composition may include, as an active principle, various substances with hepatoprotective properties, in particular, a hepatoprotector selected from the groups: amino acids or their derivatives, active hepatoprotective substances from extracts of the milk thistle plant (silymarin, silibinin), or essential phospholipids or bile acids / salts of bile acids selected from the group: XK, HDCA, DHA, UDCA, GDCA, TUDC, TXK, GCC in a single dose of 50 mg to 500 mg and a prebiotic selected from the group of indigestible farms entom of the human small intestine oligosaccharides such as lactulose or fructooligosaccharide
- FOS maltooligosaccharides or galactooligosaccharides or inulin, each taken in an effective therapeutic prebiotic dose, galactooligosaccharides, maltooligosaccharides or xylooligosaccharides, with a hepatoprotector to prebiotic ratio of 1: 2 to 1: 250.
- the claimed pharmaceutical composition may be in the form of tablets (coated or uncoated) or granules or globules or powders or capsules or suspensions or emulsions or gels.
- the claimed pharmaceutical composition may additionally contain excipients customary in the pharmaceutical industry, such as microcrystalline cellulose or lactose, or corn starch, or potato starch, or hydroxypropyl methylcellulose, or carboxymethyl cellulose, or hydroxypropylmethyl cellulose, or hydroxypropylmethyl cellulose, or hydroxypropylmethyl cellulose or calcium stearate or magnesium stearate or polysorbate or polyvinylpyrrolidone or polyethylene glycol or Falk, or titanium dioxide, or silica.
- excipients customary in the pharmaceutical industry such as microcrystalline cellulose or lactose, or corn starch, or potato starch, or hydroxypropyl methylcellulose, or carboxymethyl cellulose, or hydroxypropylmethyl cellulose, or hydroxypropylmethyl cellulose, or hydroxypropylmethyl cellulose or calcium stearate or magnesium stearate or polysorbate or polyvinylpyrrolidone or polyethylene glycol or Falk, or titanium dioxide, or silica
- the claimed composition is prepared by mixing its constituent components as active (hepatoprotector selected from the group: essential phospholipids or bile acids / bile salts and prebiotic), as well as auxiliary ones selected from the group: microcrystalline cellulose or lactose, or corn starch, or potato starch, or hydroxypropyl methyl cellulose, or carboxymethyl cellulose, or hydroxypropyl methyl cellulose, or hydroxypropyl methyl cellulose, or salts, or ludipress, or calcium stearate, or magnesium stearate, or polysorbate, or polyvinylpyrrolidone, or polyethylene glycol, or talc, or titanium dioxide, or silicon di oxide.
- active hepatoprotector selected from the group: essential phospholipids or bile acids / bile salts and prebiotic
- auxiliary ones selected from the group: microcrystalline cellulose or lactose, or corn starch, or potato starch, or hydroxypropyl methyl cellulose, or carboxymethyl
- the claimed pharmaceutical composition is administered orally with a large amount of water over a period of time from 1.5 to 3 months.
- the claimed pharmaceutical composition can be used to treat patients with liver diseases selected from the group: gallstone disease with predominantly cholesterol stones, alcoholic and nonalcoholic steatohepatitis, primary biliary cirrhosis of the liver, gall bladder cholesterosis, drug and toxic liver damage and allows for a relatively short time ( from 6 to 12 weeks) achieve long-term remission of the disease.
- liver diseases selected from the group: gallstone disease with predominantly cholesterol stones, alcoholic and nonalcoholic steatohepatitis, primary biliary cirrhosis of the liver, gall bladder cholesterosis, drug and toxic liver damage and allows for a relatively short time ( from 6 to 12 weeks) achieve long-term remission of the disease.
- therapeutic efficacy is from 89% to 95%.
- the claimed pharmaceutical composition has no contraindications and can be used to treat patients with liver diseases mentioned above, including against the background of severe concomitant diseases (with the exception of late stages of liver cirrhosis, malignant neoplasms of the gastrointestinal tract ⁇ or other organs), regardless age of the patient.
- the claimed composition does not have significant side effects, because active components included pharmaceutical compositions are used in small and medium single therapeutic doses and for a fairly short period of time.
- composition options are low cost and, therefore, available for all categories of patients.
- the proposed pharmaceutical composition can be successfully used not only for treatment, but also for the prevention of exacerbations of liver diseases selected from the group: cholelithiasis mainly with cholesterol stones, alcoholic and nonalcoholic steatohepatitis, primary biliary cirrhosis, gallbladder cholesterosis, drug and toxic damage liver, due to the restoration of the structure and function of both hepatocytes and liver function in general, due to the normalization of intestinal microflora.
- liver diseases selected from the group: cholelithiasis mainly with cholesterol stones, alcoholic and nonalcoholic steatohepatitis, primary biliary cirrhosis, gallbladder cholesterosis, drug and toxic damage liver, due to the restoration of the structure and function of both hepatocytes and liver function in general, due to the normalization of intestinal microflora.
- the impact on the body of the proposed pharmaceutical composition in a certain dose provides for a gradual and increasing strengthening of the therapeutic effect and the inclusion of new levels of homeostasis regulation: subcellular, intracellular, tissue, organ, systemic and organismic, due to restoration of lipid metabolism, in particular cholesterol, due to normalization of intestinal microbiocenosis.
- the patient is recommended to observe a regimen of at least three meals a day throughout the duration of treatment; do not recommend taking alcohol, fatty and spicy foods, other drugs; prohibit fasting and hard physical work.
- the final diagnosis is made on the basis of additional types of examinations (liver ultrasound or biliary tract R-graphy) and laboratory blood tests (biochemistry: cholesterol and its fractions, bilirubin and its fractions, alkaline phosphatase, ALT, ACT 5 ESR, etc.).
- liver damage of one degree or another: yellowness of the skin and sclera, itching of the skin, discomfort or heaviness in the right hypochondrium, dyspeptic symptoms: nausea, decreased appetite, vomiting, weakness, lethargy, discoloration of urine (darker) and stool (relief or diarrhea).
- gallstone disease for 10 years. Not operated. It is treated on an outpatient basis, without any particular effect. Worse after exercise.
- the abdomen is soft, painful at the point of Kerr. Symptoms: Kerra, Mussi and Murphy are positive. Liver on the edge of the costal arch .. In the lungs vesicular breathing. NPV 18 in 1 min.
- Coprogram muscle fibers without striation a little; fatty acids are moderate; vegetable fiber undigested - a lot; starch; single cells.
- Feces for dysbacteriosis a decrease in the number of bifido and lactobacilli, respectively: 10 5 / g, 10 6 / g, due to an increase in fungi of the genus Sapdida.
- Blood biochemistry a decrease in the number of bifido and lactobacilli, respectively: 10 5 / g, 10 6 / g, due to an increase in fungi of the genus Sapdida. Blood biochemistry:
- TP - thymol sample
- N - 4 PIECES 12.1 PIECES
- ACT - 79 PIECES N - 60 PIECES
- ALT - 72 PIECES N - 50 PIECES
- thymol sample TP
- 1.7 PIECES N - 4 PIECES
- alkaline phosphatase ALP
- ALP alkaline phosphatase
- ECG - sinus rhythm signs of moderate left ventricular hypertrophy. HELL 150/85 mm. Hg. st .; Heart rate 74 in 1 min.
- the diagnosis is final: Violation of lipid metabolism, hypercholesterolemia. Chronic calculous cholecystitis, (cholesterol stones), in the acute phase.
- Treatment use of the claimed composition, the active principles of which are hepatoprotector - UDCA and lactulose in a ratio of 1: 2 (a single dose of UDCA is 325 mg), by mouth 3 times a day with meals for 1.5 months against a diet of N ° 5.
- the skin is dry, hot to the touch.
- the skin is pale yellow, icteric sclera.
- NPV 20 in 1 min.
- the borders of the heart are extended to the left by 1, 0 cm.
- the tones are muffled.
- the rhythm is correct, accent II tone over the aorta.
- the abdomen is soft, the right edge of the liver protrudes 2.0 cm from the edge of the costal arch, the edge is dense. The spleen is not enlarged.
- Urinalysis relative density 1012; protein and glucose not detected; white blood cells 0-2-3 in n / a; erythrocytes 0-2 in s / sp .; urine amylase 14.7 mg / l.
- Coprogram muscle fibers without striation a little; fatty acids are moderate; vegetable fiber.
- KHLPVP 10.8 mmol / L (N- 0.9 - 1.9 mmol / L), low-density lipoprotein cholesterol (ChSJShNP) - 3.6 mmol / L (N - 1.91 - 2.6 mmol / l), cholesterol coefficient of atherogenicity (XKA) 3.9.e. (N - up to 3 c.u.), XXK 16.3 (N - up to 12); (norm up to 50); - protein fractions: total protein 63 g / l (N 65-85 g / l); albumin 34 g / l (N - 36-50 g / l).
- Feces for dysbiosis reduction of lactobacilli and bifidobacteria: lactobacilli (104), bifidobacteria (106).
- Liver biopsy Enhanced portal tracts are infiltrated by lymphocytes, plasma cells, macrophages and eosinophilic white blood cells. Among the cells of the portal tract infiltrates, formed lymphoid follicles are found. Infiltrates are found in the walls of some intralobular bile ducts. In some places, the integrity of the bile duct basement membrane is impaired. Near the affected bile ducts there are granulomas built from epithelioid and giant multinucleated cells.
- ECG - sinus rhythm signs of moderate left ventricular hypertrophy. HELL 150/85 mm. Hg. st .; Heart rate 76 in 1 min.
- the diagnosis is final: Violation of lipid metabolism, hypercholesterolemia. Primary biliary cirrhosis.
- Treatment use of the claimed composition, the active principles of which are hepatoprotector - HDCA and FOS in a ratio of 1: 250, (a single dose of HDCA is 250 mg) orally 3 times a day with meals for 1.5 months on the background of a Ne 5 diet.
- Ultrasound positive dynamics a decrease in fatty liver.
- the abdomen is significantly enlarged, soft, painful at the point of Kerr.
- the liver protrudes from under the edge of the costal arch at 2.5 cm thick edge.
- the spleen is not enlarged.
- NPV 22 in 1 min.
- the borders of the heart are expanded: to the right by 1.0 cm, to the left by 1.5 cm.
- the tones are muffled, the rhythm is correct, soft systolic murmur above the top of the heart.
- Pasternatsky s symptom is dubious on both sides.
- Feces for dysbacteriosis a decrease in the number of bifido and lactobacilli, 10 5 / g, 10 / g (respectively) due to an increase in fungi of the genus Sapdida.
- Blood biochemistry a decrease in the number of bifido and lactobacilli, 10 5 / g, 10 / g (respectively) due to an increase in fungi of the genus Sapdida.
- Intra- and extrahepatic bile ducts are not dilated. Signs of portal hypertension.
- Esophagogastroduodenoscopy expansion of the veins of the esophagus in / 3. ECG - sinus rhythm, signs of moderate left ventricular hypertrophy, incomplete blockade of the right leg of the bundle, blood pressure 160/85 mm. Hg. st .;
- the diagnosis is final: Violation of lipid metabolism, triglyceridemia. Fatty hepatosis. Type II diabetes mellitus. Obesity
- Treatment use of the claimed composition, the active principles of which are hepatoprotector - essential phospholipids and FOS in a ratio of 1: 50 (a single dose of essential phospholipids is 50 mg), by mouth 3 times a day with meals for 1.5 months on a diet of Ns 5 . Re-examination after 1.5 months:
- composition of UDCA and lactulose in a ratio of 1: 2 (group 1), UDCA and FOS in a ratio of 1:50 (group 2), essential phospholyshds (lecithin) and galactoligosaccharides in a ratio of 1:30 (group 3), ademethionine and lactulose in a ratio of 1 : 50 (group 4) was administered to outbred white mice weighing 15-20 g through the mouth.
- the control group (group 6) was injected with an equal amount of a suspension of starch. The animals were observed for 4 days and the general condition was recorded (appearance, mobility (activity), regularity of food and water intake, type and nature of excrement).
- the claimed pharmaceutical composition comprising hepatoprotector and a prebiotic selected from oligosaccharides not digested in the intestine as active principles can be recommended for use in clinical conditions for the treatment and prevention of liver diseases selected from the group: gallstone disease, fatty hepatosis and non-alcoholic steatohepatitis, primary biliary cirrhosis, gallbladder cholesterosis, drug and toxic liver damage.
- liver diseases selected from the group: gallstone disease, fatty hepatosis and non-alcoholic steatohepatitis, primary biliary cirrhosis, gallbladder cholesterosis, drug and toxic liver damage.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK08873197.1T DK2266619T3 (en) | 2008-03-04 | 2008-03-04 | PHARMACEUTICAL PREPARATION BASED ON A LIVING PROTECTIVE AGENT AND A PREBIOTIC AGENT, PREPARATION AND USE OF IT |
PL08873197T PL2266619T3 (pl) | 2008-03-04 | 2008-03-04 | Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie |
CN2008801288413A CN102014960A (zh) | 2008-03-04 | 2008-03-04 | 基于护肝剂和益生元的药物组合物、其制备及其应用 |
ES08873197.1T ES2545105T3 (es) | 2008-03-04 | 2008-03-04 | Composición farmacéutica a base de un agente protector hepático y de un agente prebiótico, su preparación y uso |
US12/921,383 US9446058B2 (en) | 2008-03-04 | 2008-03-04 | Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof |
SI200831478T SI2266619T1 (sl) | 2008-03-04 | 2008-03-04 | Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba |
EP08873197.1A EP2266619B1 (de) | 2008-03-04 | 2008-03-04 | Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung |
PCT/RU2008/000122 WO2009110816A1 (ru) | 2008-03-04 | 2008-03-04 | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение |
EA201001100A EA019985B1 (ru) | 2008-03-04 | 2008-03-04 | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение |
BRPI0822449-8A BRPI0822449A2 (pt) | 2008-03-04 | 2008-03-04 | Composição farmacêutica com base em hepatoprotetor e prebiótico, a produção e uso desta |
CY20151100705T CY1116601T1 (el) | 2008-03-04 | 2015-08-11 | Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της |
HRP20150849TT HRP20150849T1 (hr) | 2008-03-04 | 2015-08-11 | Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba |
US15/240,249 US20160354387A1 (en) | 2008-03-04 | 2016-08-18 | Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof |
US15/363,303 US10398717B2 (en) | 2008-03-04 | 2016-11-29 | Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2008/000122 WO2009110816A1 (ru) | 2008-03-04 | 2008-03-04 | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/921,383 A-371-Of-International US9446058B2 (en) | 2008-03-04 | 2008-03-04 | Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof |
US15/240,249 Continuation US20160354387A1 (en) | 2008-03-04 | 2016-08-18 | Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009110816A1 true WO2009110816A1 (ru) | 2009-09-11 |
Family
ID=41056233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2008/000122 WO2009110816A1 (ru) | 2008-03-04 | 2008-03-04 | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение |
Country Status (12)
Country | Link |
---|---|
US (2) | US9446058B2 (ru) |
EP (1) | EP2266619B1 (ru) |
CN (1) | CN102014960A (ru) |
BR (1) | BRPI0822449A2 (ru) |
CY (1) | CY1116601T1 (ru) |
DK (1) | DK2266619T3 (ru) |
EA (1) | EA019985B1 (ru) |
ES (1) | ES2545105T3 (ru) |
HR (1) | HRP20150849T1 (ru) |
PL (1) | PL2266619T3 (ru) |
SI (1) | SI2266619T1 (ru) |
WO (1) | WO2009110816A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104039327B (zh) * | 2012-01-06 | 2017-02-15 | 大熊制药株式会社 | 含有牛磺熊去氧胆酸的组合物 |
WO2016100228A2 (en) | 2014-12-15 | 2016-06-23 | Nanosphere Health Sciences, Llc | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids |
CN106509889A (zh) * | 2016-11-04 | 2017-03-22 | 山东维尼莱生物科技股份有限公司 | 一种对酒精性肝损伤有辅助保护作用的保健品 |
JP6772773B2 (ja) * | 2016-11-14 | 2020-10-21 | ブラザー工業株式会社 | 通信装置 |
CN111494333B (zh) * | 2020-04-14 | 2022-06-14 | 安士制药(中山)有限公司 | 一种熊去氧胆酸胶囊及其制备方法 |
EP4147706A1 (en) * | 2020-05-05 | 2023-03-15 | Abou Nehmi Filho, Victor | Composition for regulating the neuro-immune-endocrine system |
CN115040545A (zh) * | 2022-06-13 | 2022-09-13 | 江南大学 | 鸡胆粉在制备解酒护肝药物中的用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003155242A (ja) | 2001-11-19 | 2003-05-27 | Nippon Beet Sugar Mfg Co Ltd | 肝機能改善剤 |
RU2205637C1 (ru) * | 2002-04-24 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Гепатопротекторное средство "карсилин" |
RU2002123352A (ru) | 2000-02-04 | 2004-03-27 | Сео Хонг Ю (US) | Получение водного прозрачного раствора лекарственных форм с желчными кислотами |
BG108250U (en) | 2003-10-10 | 2005-04-30 | "Софарма" Ад | Probiotic food additive |
RU2310463C1 (ru) * | 2006-05-19 | 2007-11-20 | Закрытое акционерное общество "Партнер" | Гепатопротекторный пробиотик |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1283225B1 (it) * | 1996-03-11 | 1998-04-16 | Renata Maria Anna Ve Cavaliere | Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle |
CZ20033042A3 (cs) * | 2003-11-10 | 2005-06-15 | Naturprodukt Cz Spol. S R. O. | Potravinový doplněk na bázi silymarinu |
HUP0500582A1 (hu) * | 2005-06-13 | 2007-08-28 | Csaba Jozsef Dr Jaszberenyi | Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok |
-
2008
- 2008-03-04 CN CN2008801288413A patent/CN102014960A/zh active Pending
- 2008-03-04 US US12/921,383 patent/US9446058B2/en active Active
- 2008-03-04 ES ES08873197.1T patent/ES2545105T3/es active Active
- 2008-03-04 WO PCT/RU2008/000122 patent/WO2009110816A1/ru active Application Filing
- 2008-03-04 DK DK08873197.1T patent/DK2266619T3/en active
- 2008-03-04 EP EP08873197.1A patent/EP2266619B1/de active Active
- 2008-03-04 SI SI200831478T patent/SI2266619T1/sl unknown
- 2008-03-04 BR BRPI0822449-8A patent/BRPI0822449A2/pt not_active IP Right Cessation
- 2008-03-04 PL PL08873197T patent/PL2266619T3/pl unknown
- 2008-03-04 EA EA201001100A patent/EA019985B1/ru not_active IP Right Cessation
-
2015
- 2015-08-11 CY CY20151100705T patent/CY1116601T1/el unknown
- 2015-08-11 HR HRP20150849TT patent/HRP20150849T1/hr unknown
-
2016
- 2016-08-18 US US15/240,249 patent/US20160354387A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2002123352A (ru) | 2000-02-04 | 2004-03-27 | Сео Хонг Ю (US) | Получение водного прозрачного раствора лекарственных форм с желчными кислотами |
JP2003155242A (ja) | 2001-11-19 | 2003-05-27 | Nippon Beet Sugar Mfg Co Ltd | 肝機能改善剤 |
RU2205637C1 (ru) * | 2002-04-24 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Гепатопротекторное средство "карсилин" |
BG108250U (en) | 2003-10-10 | 2005-04-30 | "Софарма" Ад | Probiotic food additive |
RU2310463C1 (ru) * | 2006-05-19 | 2007-11-20 | Закрытое акционерное общество "Партнер" | Гепатопротекторный пробиотик |
Non-Patent Citations (18)
Also Published As
Publication number | Publication date |
---|---|
PL2266619T3 (pl) | 2015-10-30 |
EP2266619B1 (de) | 2015-05-13 |
BRPI0822449A2 (pt) | 2015-06-16 |
EA201001100A1 (ru) | 2011-02-28 |
US9446058B2 (en) | 2016-09-20 |
EP2266619A1 (de) | 2010-12-29 |
ES2545105T3 (es) | 2015-09-08 |
US20160354387A1 (en) | 2016-12-08 |
EA019985B1 (ru) | 2014-07-30 |
SI2266619T1 (sl) | 2015-11-30 |
CY1116601T1 (el) | 2017-03-15 |
EP2266619A4 (de) | 2011-07-20 |
US20110312910A1 (en) | 2011-12-22 |
DK2266619T3 (en) | 2015-08-24 |
CN102014960A (zh) | 2011-04-13 |
HRP20150849T1 (hr) | 2015-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160354387A1 (en) | Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof | |
KR102051030B1 (ko) | 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제 | |
EP4241840A2 (en) | Methods for treating cholestasis | |
Trauner et al. | Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases | |
EP0906106B1 (en) | Prevention and treatment of colonic adenoma or colonic microadenoma by 6-fluoroursodeoxycholic acid (6-fudca) | |
JP2016514684A (ja) | 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤 | |
JP2009511577A (ja) | 胃腸疾患用胆汁製剤 | |
RU2318538C1 (ru) | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение | |
ES2962302T3 (es) | Tratamiento de la colestasis intrahepática y hepatopatías relacionadas | |
US10398717B2 (en) | Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating | |
EP1158989A2 (en) | Use of inhibitors of endotoxin for the treatment of chachexia | |
Meeberg et al. | Therapy with ursodeoxycholic acid in cholestatic liver disease | |
UA93849C2 (ru) | Фармацевтическая композиция ha ochobe гепатопротектора и пребиотика и ee получение | |
Mikov et al. | Potentials and limitations of bile acids and probiotics in diabetes mellitus | |
Hofmann | Targeting drugs to the enterohepatic circulation: lessons from bile acids and other endobiotics | |
LU504581B1 (en) | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | |
RU2306943C1 (ru) | Способ лечения гиперхолестеринемических состояний у больных с желчнокаменной болезнью путем применения препарата "гепатосан", ускоряющего окисление холестерина в печени | |
Fiaschini | The role of intestinal inflammation on the gut-liver axis | |
US5935948A (en) | Method of treating and preventing gallstones | |
RU2519198C2 (ru) | Способ лечения больных желчекаменной болезнью первой стадии | |
WO2007026742A1 (ja) | 大腸デリバリー型炎症性大腸疾患治療薬 | |
Angelico et al. | Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis | |
HALE | The effect of the digestive secretions on the activity of digitalis and allied drugs | |
Mir et al. | EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH SIMVASTATIN IN HIPERCHOLESTEROLEMIC KIDNEY TRANSPLANT PATIENTS. | |
Bayés et al. | ORAL GLUCOSE OVERLOAD AND VASCULAR LESION IN RENAL TRANSPLANTION. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880128841.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08873197 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201001100 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008873197 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12921383 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0822449 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100903 |